• An Open Letter to FDA’s New Commissioner
    An Open Letter to FDA’s New Commissioner
    By: Cynthia Pearson Dear Commissioner, I wish you well. Honestly, I do. You’ve got a big job with, well, challenging bosses. But you know what? We’re your bosses, too. The public pays for more than half of the Food and Drug Administration’s (FDA) budget each year, which entitles us to have a say in the agency’s  operations. ...
  • A New Treatment for Postpartum Depression: Boon or Bane?
    A New Treatment for Postpartum Depression: Boon or Bane?
    By Sophie Krensky and Olivia Shannon Last November, the Food and Drug Administration’s (FDA) Reproductive Health Drugs Advisory Committee voted overwhelmingly in favor of brexanolone, a first-of-its-kind treatment for postpartum depression (PPD). We question whether brexanolone will help mothers or if it’s a misdirected silver bullet for a larger, more insidious problem: lack of support ...
  • Brightness Among the Clouds: Positive Women’s Health Efforts at the FDA
    Brightness Among the Clouds: Positive Women’s Health Efforts at the FDA
    By Eliana Kosova In our current political climate, each day brings new attacks on reproductive health. Between the Trump-Pence Administration’s attacks on access to birth control and Congress’s continual efforts to curtail abortion care, we are in an uphill battle when it comes to reproductive freedom. When Scott Gottlieb was tapped as Commissioner of the Food ...
  • The Long Road to Long-term Treatment: Evaluating the State of Uterine Fibroids Medication
    The Long Road to Long-term Treatment: Evaluating the State of Uterine Fibroids Medication
    By Eliana Kosova For some, finding the right medication to treat their medical condition is as simple as consulting a doctor and picking up a prescription. For many others, it’s a waiting game. Unfortunately, for those with uterine fibroids, the situation is more often the latter than the former. Although anywhere from 20 to 80 percent of ...
  • Addyi Update
    Addyi Update
    By Negar Esfandiari and Kara Cotto  In 2015, Valeant, a pharmaceutical giant known for price gouging and shady business practices paid $1 billion in cash for a flawed sexual enhancement drug marketed to women with so-called “acquired generalized hypoactive sexual desire disorder.” The drug, flibanserin, is sold under the name “Addyi,” and is described as the female version of Viagra. Despite the huge amounts of money involved, the drug’s a bust. It’s crucial for women to understand the small pink pill’s dangerous ...
  • Keep Passing on the Pink Pill: DON’T “Get Addyi Now”!
    Keep Passing on the Pink Pill: DON’T “Get Addyi Now”!
    By Abby Miller and Susan K. Flinn What do you do when your product isn’t popular and sales have slumped? Gin up an advertising campaign to convince consumers that they absolutely have to have what you’re selling. Flibanserin (brand name “Addyi”) is the first drug approved by the Food and Drug Administration (FDA) to treat so-called “Hypoactive Sexual Desire Disorder” ...